EGFR and non-small cell lung carcinoma: Osimertinib is the third-generation for the treatment of patients with metastatic EGFR T790M-positive NSCLC (Cross et al., 2014), which is the first compound granted US Food and Drug Administration (FDA) and European Medicine Agency (EMA) approval (Santarpia et al., 2017b).